Chemistry:Enavogliflozin

From HandWiki

Enavogliflozin (DWP16001/GCC5694A) is a selective SLC5A2 and SGLT2 inhibitor developed to treat diabetes and obesity.[1][2][3][4][5] It was developed by GC Pharma[6][7] and Daewoong Pharmaceutical.[7]

Enavogliflozin has been approved for clinical use in South Korea,[7] and Ecuador,[8] and applied for approval in Brazil, Mexico, Peru, and Colombia.[8]

References

  1. ↑ Hwang, Jun Gi; Lee, SeungHwan; Huh, Wan; Han, Jumi; Oh, Jaeseong; Jang, In-Jin; Yu, Kyung-Sang (September 2022). "Dose-dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter-2 inhibitor, in healthy subjects". British Journal of Clinical Pharmacology 88 (9): 4100–4110. doi:10.1111/bcp.15348. PMID 35395697. 
  2. ↑ Kim, Ju-Hyun; Kim, Dong Kyun; Choi, Won-Gu; Ji, Hye-Young; Choi, Ji-Soo; Song, Im-Sook; Lee, Sangkyu; Lee, Hye Suk (11 September 2020). "In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes". Pharmaceutics 12 (9): 865. doi:10.3390/pharmaceutics12090865. PMID 32932946. 
  3. ↑ Kim, Byungwook; Huh, Ki Young; Hwang, Jun Gi; Nah, JaeJin; Huh, Wan; Cho, Jae Min; Jang, In-Jin; Yu, Kyung-Sang et al. (April 2023). "Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium–glucose cotransporter 2 inhibitor and metformin in healthy subjects". British Journal of Clinical Pharmacology 89 (4): 1462–1470. doi:10.1111/bcp.15613. PMID 36422809. 
  4. ↑ Rhee, Beomseok; Mahbubur, Rahman Md; Jin, Changfan; Choi, Ji-Soo; Lim, Hyun-Woo; Huh, Wan; Park, Joon Seok; Han, Jumi et al. (December 2022). "Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs". BMC Veterinary Research 18 (1): 237. doi:10.1186/s12917-022-03324-2. PMID 35733159. 
  5. ↑ Yoon, Sukyong; Park, Min Soo; Jin, Byung Hak; Shin, Hyobin; Na, Jaejin; Huh, Wan; Kim, Choon Ok (3 July 2023). "Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects". Expert Opinion on Drug Metabolism & Toxicology 19 (7): 479–485. doi:10.1080/17425255.2023.2249397. PMID 37593838. 
  6. ↑ Kong, Young Kyu; Song, Kwang-Seop; Jung, Myung Eun; Kang, Misuk; Kim, Hyeon Jung; Kim, Min Ju (2022-01-15). "Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes". Bioorganic & Medicinal Chemistry Letters 56. doi:10.1016/j.bmcl.2021.128466. ISSN 0960-894X. https://linkinghub.elsevier.com/retrieve/pii/S0960894X21006934. 
  7. ↑ 7.0 7.1 7.2 Kim, Min-Soo; Song, Yoo-Kyung; Choi, Ji-Soo; Ji, Hye Young; Yang, Eunsuk; Park, Joon Seok; Kim, Hyung Sik; Kim, Min-Joo et al. (2023-03-14). "Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans" (in en). Pharmaceutics 15 (3): 942. doi:10.3390/pharmaceutics15030942. ISSN 1999-4923. PMID 36986803. 
  8. ↑ 8.0 8.1 "Daewoong Pharmaceutical's diabetes drug wins approval in Ecuador - 매일경제 영문뉴스 펄스(Pulse)" (in ko). 2024. https://pulse.mk.co.kr/news/english/11139317. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Enavogliflozin&oldid=4179785"